Loading
companiesCompany
Orion, Orion Pharma
Orion, Orion Pharma is a Finland-based pharmaceutical company running 4 late-stage cancer trials of ODM-212, ODM-216 and sotorasib in mesothelioma, pancreatic ductal adenocarcinoma and non-small-cell lung cancer.
Also called: Orion Corporation, Orion Pharma
Overview
Orion, Orion Pharma, based in Espoo, Finland, is a pharmaceutical company. Orion Pharma is a Finnish pharmaceutical company that develops and manufactures medicines across oncology, respiratory disease, neurological disease, women's health and pain management, as well as veterinary medicines and active pharmaceutical ingredients. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing ODM-212, ODM-216, sotorasib and ODM-208 in mesothelioma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer and prostate cancer. The largest, NCT06725758 (A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Mesothelioma, Prostate cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Shares Mesothelioma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- TreatmentOpevesostat
Shares Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer, Prostate cancer.
- TargetMGA
Shares Mesothelioma, Prostate cancer, Non-small-cell lung cancer.
- TargetVISTA
Shares Mesothelioma, Pancreatic ductal adenocarcinoma, Prostate cancer, Non-small-cell lung cancer.
- TargetSETD2
Shares Mesothelioma, Pancreatic ductal adenocarcinoma, Prostate cancer.
- TargetERCC1
Shares Mesothelioma, Non-small-cell lung cancer.
- CompanyA2 Biotherapeutics
Shares Mesothelioma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
cancers
trials
A 2-part Phase 1/2 Open-label Trial on ODM-212A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid TumoursSafety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerTrial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer